Navigation Links
CerSci Therapeutics Awarded $225K Phase I NIH SBIR Grant for the Treatment of Neuropathic Pain
Date:3/8/2017

DALLAS, March 8, 2017 /PRNewswire/ -- CerSci Therapeutics, a pharmaceutical development company based in Dallas, Texas, today announced it has been awarded a Phase I SBIR grant of $225,000 from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) to continue its development of novel non-opioid drug candidates for the treatment of chronic neuropathic pain. 

CerSci Therapeutics, founded in early 2015, is focused on developing next-generation non-opioid pain therapeutics for the treatment and prevention of acute and chronic pain. This grant will enable CerSci to further develop their patented and patent-pending pipeline of adenosine monophosphate activated protein kinase (AMPK) activators and peroxynitrite (PN) scavengers.  CerSci's development of non-opioid pain therapeutics addresses the critical need of finding solutions to the opioid epidemic in the U.S.  According to the U.S. Center for Disease Control, the United States is in the midst of an opioid overdose epidemic; opioids killed more than 33,000 Americans (90 people per day) in 2015, with half of all opioid overdose deaths involving a prescription opioid.

"Healthcare expenditures associated with chronic pain account for over $600 billion annually, more than the yearly cost of cancer, and heart disease combined. However, treatments available for these patients are very limited," remarked Dr. Lucas Rodriguez, Co-Founder and President of CerSci Therapeutics. "Alarmingly, 1 in 4 patients who treat chronic pain with opioids struggle with addiction. At CerSci, we believe that developing drugs, which avoid interaction with opioid receptors altogether, will aid in the relief of the opioid epidemic while providing caregivers drugs, which will truly help alleviate their patients' pain. We are incredibly energized to receive this validation from our peers at the NIH."

CerSci Therapeutics is currently fundraising to support the Investigational New Drug Application for their lead molecular asset to the Food and Drug Administration.

Media Contact:
Lucas Rodriguez
+1 (956) 279-6888
www.cersci.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cersci-therapeutics-awarded-225k-phase-i-nih-sbir-grant-for-the-treatment-of-neuropathic-pain-300419617.html


'/>"/>
SOURCE CerSci Therapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Dermatology Diagnostic Devices and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
2. Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results
3. Bellerophon Therapeutics and Worldwide Clinical Trials Selected as Finalists in 2017 Care Awards
4. ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on March 9, 2017
5. Mast Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
6. Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease
7. How These Biotech Stocks are Faring? -- Geron, Incyte, Illumina, and Bellerophon Therapeutics
8. Nektar Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting
9. Global Breast Cancer Therapeutics Market Analysis 2016-2022: Company Profiling Covering the Financials, Recent Activities and Future Strategies - Research and Markets
10. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Strategic Business Report 2017-2022 - Research and Markets
11. United Therapeutics Corporation To Present At Cowen And Company 37th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... July 28, 2017 EnvoyHealth, a Diplomat company, has ... program for CleverCap LITE, a technology designed to improve ... deliver innovative health technology solutions and services that help ... CleverCap LITE offers medication monitoring and ... cover: Records date ...
(Date:7/27/2017)... Services, Inc. (NYSE: WST ) today announced ... financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record high, ... constant currency (organic) grew by 3.9%. ... in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS ...
(Date:7/26/2017)... Medical Aesthetics, a leading medical aesthetic clinic in Singapore ... several skin conditions from the inside. The natural process ... The skin becomes more transparent due to the thinning of the ... from the sun contributes to aging skin, causing age spots and ... ...
Breaking Medicine Technology:
(Date:8/17/2017)... , ... August 17, 2017 , ... ... The Journey to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, eBook, 9781498497633) ... to encourage inner healing of memories and achieve forgiveness, through a progressive journey ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Momkus McCluskey ... newest Partner. Ms. Parks is a member of the firm’s Commercial Litigation and Employment ... and provides a wealth of knowledge in matters of employment litigation, commercial litigation and ...
(Date:8/17/2017)... ... 2017 , ... A recent report indicates that circa 79 percent of 483 ... in data integrity. The FDA outlines their expectations for quality critical instrumentation in the ... of the Beckman Coulter Life Sciences Virtual Trade Show Virtual Event, this ...
(Date:8/16/2017)... ... 2017 , ... Blue Health Intelligence (BHI) announced today that Dr. ... Spiro brings over 30 years of clinical, healthcare IT, value-based care, and change management ... , “I am thrilled to welcome Dr. Spiro to BHI,” said Swati Abbott, ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, ... that it was acquired by Advantage Solutions. The Data Council’s IX-ONE platform ... include the industry’s leading suppliers, brokers, distributors and retailers. The Data Council will ...
Breaking Medicine News(10 mins):